GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Haisco Pharmaceutical Group Co Ltd (SZSE:002653) » Definitions » Return-on-Tangible-Equity

Haisco Pharmaceutical Group Co (SZSE:002653) Return-on-Tangible-Equity : 18.00% (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Haisco Pharmaceutical Group Co Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Haisco Pharmaceutical Group Co's annualized net income for the quarter that ended in Mar. 2024 was ¥368 Mil. Haisco Pharmaceutical Group Co's average shareholder tangible equity for the quarter that ended in Mar. 2024 was ¥2,043 Mil. Therefore, Haisco Pharmaceutical Group Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was 18.00%.

The historical rank and industry rank for Haisco Pharmaceutical Group Co's Return-on-Tangible-Equity or its related term are showing as below:

SZSE:002653' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 14   Med: 22.89   Max: 40.71
Current: 18.09

During the past 13 years, Haisco Pharmaceutical Group Co's highest Return-on-Tangible-Equity was 40.71%. The lowest was 14.00%. And the median was 22.89%.

SZSE:002653's Return-on-Tangible-Equity is ranked better than
92.31% of 1301 companies
in the Biotechnology industry
Industry Median: -46.42 vs SZSE:002653: 18.09

Haisco Pharmaceutical Group Co Return-on-Tangible-Equity Historical Data

The historical data trend for Haisco Pharmaceutical Group Co's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haisco Pharmaceutical Group Co Return-on-Tangible-Equity Chart

Haisco Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.12 40.71 22.57 22.75 19.03

Haisco Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.61 9.65 25.83 18.95 18.00

Competitive Comparison of Haisco Pharmaceutical Group Co's Return-on-Tangible-Equity

For the Biotechnology subindustry, Haisco Pharmaceutical Group Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haisco Pharmaceutical Group Co's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Haisco Pharmaceutical Group Co's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Haisco Pharmaceutical Group Co's Return-on-Tangible-Equity falls into.



Haisco Pharmaceutical Group Co Return-on-Tangible-Equity Calculation

Haisco Pharmaceutical Group Co's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=295.112/( (1096.046+2004.869 )/ 2 )
=295.112/1550.4575
=19.03 %

Haisco Pharmaceutical Group Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=367.824/( (2004.869+2081.754)/ 2 )
=367.824/2043.3115
=18.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Haisco Pharmaceutical Group Co  (SZSE:002653) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Haisco Pharmaceutical Group Co Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Haisco Pharmaceutical Group Co's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Haisco Pharmaceutical Group Co (SZSE:002653) Business Description

Traded in Other Exchanges
N/A
Address
No. 17, Sanxiang Avenue, Shannan District, Tibet Autonomous Region, Zetang, CHN, 856000
Haisco Pharmaceutical Group Co Ltd is a pharmaceutical company based in China. It is mainly engaged in the research, development, manufacture, and sale of drugs for liver disease. Its product portfolio includes parenteral nutrition drugs, antibiotics, anesthetic agents, digestive system drugs and tumour adjuvant drug series. The company's products are being used in first rank hospitals in China.
Executives
Fan Xiu Lian Directors, executives
Zheng Wei Directors, executives
Wang Meng Secretary Dong
Wang Jun Min Directors, executives
Deng Xiang Directors, executives
Liu Han Bing Supervisors
Zhang Xiao Xu Supervisors
Tan Hong Executives
Shen Ping Director
Liang Yong Supervisors
Chen Long Independent director
Duan Qing Liang Supervisors

Haisco Pharmaceutical Group Co (SZSE:002653) Headlines

No Headlines